ValiRx plc (LON:VAL – Get Free Report) rose 11.6% on Tuesday . The company traded as high as GBX 2.80 ($0.04) and last traded at GBX 2.68 ($0.03). Approximately 914,043 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 1,169,071 shares. The stock had previously closed at GBX 2.40 ($0.03).
ValiRx Price Performance
The firm has a 50-day moving average of GBX 2.73 and a 200-day moving average of GBX 3.53. The stock has a market cap of £3.78 million, a PE ratio of -142.75 and a beta of 0.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.64 and a quick ratio of 1.27.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Read More
- Five stocks we like better than ValiRx
- What is the Shanghai Stock Exchange Composite Index?
- Meta Platforms: Rotation or Not, It’s Rally On For This AI Stock
- The Significance of Brokerage Rankings in Stock Selection
- Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
- How Investors Can Find the Best Cheap Dividend Stocks
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
